PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSavolitinib
Savolitinib
Savolitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target hepatocyte growth factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289——384——14
Lung neoplasmsD008175HP_0100526C34.90181—111
NeoplasmsD009369—C80722——11
Renal cell carcinomaD002292EFO_0000376——42——6
CarcinomaD002277—C80.0—42——6
Kidney diseasesD007674EFO_0003086N08——1——1
Urologic neoplasmsD014571—C64-C68——1——1
Kidney neoplasmsD007680EFO_0003865C64——1——1
Neoplasms by siteD009371————1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230——15———5
Stomach neoplasmsD013274EFO_0003897C1612———3
Colorectal neoplasmsD015179——11———2
Prostatic neoplasmsD011471—C61—1———1
Clear cell adenocarcinomaD018262———1———1
AdenomyoepitheliomaD055331———1———1
Colonic neoplasmsD003110—C18—1———1
Rectal neoplasmsD012004———1———1
MutationD009154———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
Therapeutic equivalencyD013810——1————1
RecurrenceD012008——1————1
GliomaD005910EFO_0000520—1————1
Central nervous system neoplasmsD016543——1————1
MedulloblastomaD008527——1————1
Nervous system neoplasmsD009423——1————1
Diffuse intrinsic pontine gliomaD000080443——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSavolitinib
INNsavolitinib
Description
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
Identifiers
PDB—
CAS-ID1313725-88-0
RxCUI—
ChEMBL IDCHEMBL3334567
ChEBI ID—
PubChem CID—
DrugBankDB12048
UNII ID2A2DA6857R (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MET
MET
Organism
Homo sapiens
Gene name
MET
Gene synonyms
NCBI Gene ID
Protein name
hepatocyte growth factor receptor
Protein synonyms
HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met
Uniprot ID
Mouse ortholog
Met (17295)
hepatocyte growth factor receptor (Q62125)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,177 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
65 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use